CURRICULUM VITAE
YASER HOMSI, M.D

yaserh@pacshoresoncology.com

Active medical license: California (Lic# 145827)
DEA: FH6880644
NPI: 1790943983

EDUCATION:
ACADEMIC DEGREES AND QUALIFICATIONS:

2003 M.D (Doctor of Medicine Diploma)
University of Aleppo
Aleppo, Syria

2005 ECFMG Certification
Educational Commission for Foreign Medical Graduates,
Philadelphia, PA

2008 Board certified in Internal Medicine by American Board of internal medicine (ABIM)

2012 Board certified in Medical Oncology by ABIM

2012 Board certified in Hematology by ABIM

POSITIONS HELD AND EXPERIENCE:

December 2019 -Current

Pacific Shores Medical Group

Jan 1, 2019 -November 2019
Medical Director for Riverside County
The Oncology Institute of Hope and Innovation

Aug 24, 2017- December 2019
Hematology and Oncology Specialist at Riverside Community Hospital
The Oncology Institute of Hope and Innovation

July 1, 2015- Aug 11, 2017 Director of clinical research
WVU Medicine /United Hospital Center

January 1, 2014- Aug 11, 2017 Hematology and Oncology Specialist
WVU Medicine /United Hospital Center

January 1, 2014- Aug 11, 2017 Director of Cancer services and Infusion Center
Stonewall Jackson memorial Hospital

Nov 20, 2012- Aug 11, 2017 Clinical Assistant Professor (secondary appointment)
Department of Medicine

Division of Hematology and Oncology

July 1, 2012- Dec 31, 2013 Hematology and Oncology Specialist
Associated Specialists, Inc/United Hospital Center

July 1, 2009- June 23, 2012 Fellow in Hematology and Oncology
Department of Medicine
Division of Hematology and Oncology

July 1, 2008- June 30, 2009 Fellow in Blood and Bone Marrow Stem cell Transplant
Department of Medicine
Division of Hematology and Oncology
Indiana University School of Medicine, Indianapolis, Indiana

July 1, 2006- June 30, 2008 Internal Medicine Resident
Department of Medicine
Indiana University School of Medicine, Indianapolis, Indiana

July 1, 2005- June 30, 2006 Internal Medicine Intern
Department of Medicine
Indiana University School of Medicine, Indianapolis, Indiana

Oct 1, 2003- April 30, 2005 Pathology Resident
Department of Surgical Pathology
University of Aleppo, Aleppo, Syria

TEACHING

Jan 1, 2013 – Aug 2017 Monthly Hematology and Oncology Lecture
Family Medicine Residency Program
WVU Medicine /United Hospital Center

BOARD CERTIFICATION

Internal Medicine American Board of internal medicine (ABIM)

Medical Oncology American Board of internal medicine (ABIM) subspecialty

Hematology American Board of internal medicine (ABIM) subspecialty

MEMBERSHIP OF PROFESSIONAL SOCIETIES:

2011- current American Society of Clinical Oncology (ASCO)

2009- current American Society of Hematology (ASH)

ABSTRACTS:

Yaser Homsi, Dareen Alwan, Patrick Kiel, Lindsay Rosenbeck, Srivastava Shivani, Jennifer E. Schwartz,

Robert P. Nelson, Jr., Rafat Abonour, Michael Robertson, and Sherif Farag. The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 2345.

Yaser Homsi, Li Chen, Shuhong Zhang, Jing Liang, Attaya Suvannasankha, Rafat Abonour, and Sherif Farag. Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A Potential Target for Immunotherapy. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3031

Shuhong Zhang, Jing Liang, Li Chen, Yaser Homsi, Xiaojing Wang, Hailin Feng, Shivani Srivastava, Sherif S. Farag. Enhanced NK cell mediated cytotoxicity against multiple myeloma (MM) cells by the combination of anti-KIR (1-7F9) monoclonal antibody (mAb) and lenalidomide. AACR 100th Annual Meeting 2009, Abstract#3245

PRESENTATIONS

1. Bone Marrow Transplant, Chairman Conference, Department of Internal Medicine, Indiana

University School of Medicine, Indianapolis, IN. (10/23/2007)

2. Multiple Myeloma Derived Factors Generate Tolerogenic Dendritic Cells by Activation of STAT3: A potential Target in immunotherapy, oral presentation at Thirteenth Annual Fellow Research Competition, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN. (5/15/2009)

PUBLICATIONS

Yaser Homsi, Dareen Alwan, Patrick Kiel, Lindsay Rosenbeck, Srivastava Shivani, Jennifer E. Schwartz, Robert P. Nelson, Jr., Rafat Abonour, Michael Robertson, and Sherif Farag. The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors. [Pending Submission to Biology of Blood and Marrow Transplantation]

Homsi Y, Homsi, M, Alsayed L, Akael N, Role of Angiogenesis in Cancer, University of Aleppo Publications, Aug 2003. (Thesis for M.D)

HONORS

1. 2nd place winner for the Thirteenth Annual Fellow Research Competition, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN. (5/15/2009)

RESEARCH

7/1/08-6/30/12 Cellular Therapy and hematopoietic Stem Cell Transplantation for cancer, Indiana University, IN. Title: STAT3 Inhibition to enhance the immune response of Dendritic cells against Multiple Myeloma. PI: Yaser Homsi, M.D./Sherif Farag M.D.,Ph.D.

The overall objective of this project is to study the effect of STAT3 inhibition on human Dendritic cells, with the aim of identifying the optimal condition of inhibition for the purpose of enhancing the immune response against Multiple Myeloma. The results will provide preclinical rationale to clinically investigate the use of STAT3 inhibitors in future immunotherapy clinical trials.

12/15/10-ongoing The Outcome of AML Patients who failed one cycle of 7+3
PI: Yaser Homsi, M.D./Larry Cripe, MD.
Co-PI: Dareen Alwan. M.D

This is a retrospective study looking the outcome of 112 patients with AML that treated at Indiana University between 1990 and 2010, which where refractory to 1 cycle of 7+3. End points are the rate of successful salvage therapy, disease free survival, and overall survival.

2/2011-6/2012 Treatment Preferences of Patients with Advanced Non-Small Cell Lung Cancer
PI: Yaser Homsi, M.D./Nasser Hanna, M.D
Co-PI: Patrick Loehrer MD

The primary goal of this study is to develop and pilot-test a survey to understand patient preferences in the treatment of advanced NSCLC. It is hoped that we will also be able to develop a quantitative description of the value that patients assign to attributes of various treatment regimens in NSCLC.

12/1/09-6/30/2010 Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis
PI: Yaser Homsi, M.D./Sherif Farag M.D.,Ph.D.
Co-PI: Dareen Alwan. M.D

This is a retrospective study comparing the outcomes of matched unrelated donor using tacrolimus, sirolimus, and ATG for GvHD prophylaxis with those who received cyclosporine/Methotrexate.

8/1/07-10/30/08 Title: Optimizing T Cell Receptor Excision Circle (TREC) Assay and T Cell Receptor (TCR) Spectratyping Assay for a Clinical Study Application.
PI: Yaser Homsi, M.D./Sherif Farag M.D.,Ph.D.

The overall objective of this project was to optimize the condition of two assays (TREC Assay and TCR Spectratyping) for clinical application within the ongoing clinical trial IUCRO-0184 (Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34+ Cells in Patients with Hematological Malignancies).